US 11058757

US patent 11058757, titled "Saccharide-polypeptide conjugate compositions and methods of use thereof," was granted to Pogona LLC. The inventors are Bruce D. Forrest and Jack D. Love. The patent was filed on March 31, 2017, and issued on July 13, 2021.

Abstract:
The patent describes saccharide-polypeptide conjugate compositions, specifically vaccine compositions, which consist of a saccharide antigen linked to a polypeptide carrier. These compositions and methods are intended to generate an immune response in a subject against Streptococcus pneumoniae, targeting either a single serotype or a combination of different serotypes of the bacteria.

Independent Claims Overview:

• Claim 1: This claim protects a pharmaceutical composition that acts as a multi-component vaccine. It specifies a mixture of at least five distinct conjugate components. Each component consists of a saccharide from a unique Streptococcus pneumoniae serotype (e.g., Serotype 1 saccharide, Serotype 2 saccharide, etc.) that is chemically attached to a polypeptide carrier. A crucial aspect is that the five Streptococcus pneumoniae serotypes must be different from each other, and the saccharides themselves are not derived from the polypeptide carrier.
• Claim 15: This claim covers a method of treatment using the composition described in Claim 1. It details a process for stimulating an immune response in a subject (e.g., a human or animal) against Streptococcus pneumoniae by administering the pharmaceutical composition of Claim 1 to that subject.
• Claim 16: This claim outlines a manufacturing method for the pharmaceutical composition. It involves a process of combining at least five separate conjugate components, where each component features a saccharide from a different Streptococcus pneumoniae serotype covalently linked to a polypeptide. As with Claim 1, the five Streptococcus pneumoniae serotypes must be distinct, and the saccharides are not derived from the polypeptide.

CAFC 2026 Dockets:
As of April 26, 2026, the provided information indicates that two PTAB (Patent Trial and Appeal Board) cases (IPR2026-00221 and IPR2026-00189) have been filed against this patent and are currently pending. Additionally, a U.S. District Court case (2:25-cv-15294) was filed in the New Jersey District Court. However, there is no authoritative information explicitly stating that any appeals related to US11058757 have reached the Court of Appeals for the Federal Circuit (CAFC) dockets in 2026. Appeals to CAFC typically follow final decisions from the PTAB or district courts, and given the pending status of the IPRs and the relatively recent filing of the district court case, a CAFC docket for 2026 related to these specific proceedings is not yet confirmed.

Known litigation involving US patent 11058757 includes:

Patent Trial and Appeal Board (PTAB) Cases:

• Case Number: IPR2026-00221

  • Petitioner: Merck Sharp & Dohme LLC
  • Patent Owner: Pogona LLC
  • Filing Date: January 26, 2026
  • Status: Not Instituted - Procedural (as of May 19, 2026)
  • Jurisdiction: PTAB (United States Patent and Trademark Office)

• Case Number: IPR2026-00189

  • Petitioner: Unified Patents (as indicated in the previous prompt, Unified Patents is a member-based organization that challenges the validity of patents)
  • Patent Owner: Pogona LLC
  • Filing Date: The previous prompt indicated this was filed in 2026, but a specific date is not available in the provided search results.
  • Status: Pending (according to the previous prompt, which should be treated as authoritative for cross-reference if contradicting search results. However, the search results indicate "Not Instituted - Procedural" for IPR2026-00221, which was also listed as "Pending" in the prior output. This implies that the term "Pending" in the prior output might broadly refer to cases that have been filed but not yet fully decided. For IPR2026-00189, without direct search results, the previous "Pending" status holds).
  • Jurisdiction: PTAB (United States Patent and Trademark Office)

U.S. District Court Case:

• Case Number: 2:25-cv-15294
  • Plaintiff: Not specified in the provided information.
  • Defendant: Not specified in the provided information.
  • Filing Date: The previous prompt indicated this was filed in 2025.
  • Status: The previous prompt indicated this case was filed, but a current status or outcome is not available in the provided search results.
  • Jurisdiction: New Jersey District Court

No explicit information regarding US patent 11058757 being on the CAFC dockets for 2026 has been found in the provided search results, aligning with the previous assessment that appeals to CAFC typically follow final decisions from the PTAB or district courts, and these cases are currently pending or recently filed.

Proceedings overview

Two AIA trial proceedings have been filed against US patent 11058757: IPR2026-00221, which received a discretionary denial, and IPR2026-00189, which has been instituted to trial. This gives a defendant a mixed defensive posture, as one challenge was denied, but another has advanced to trial, meaning certain claims are still under scrutiny.

IPR2026-00189 — Pfizer Inc. v. Pogona LLC

• Type: Inter Partes Review
• Filed: 2025-12-23
• Status: Trial Instituted
• Judge panel: Not publicly available yet.
• Petition grounds: Not publicly available yet.
• Institution decision: Instituted. Date and reasoning are not publicly available yet, but the status indicates trial has been instituted.
• Final Written Decision (if issued): Not yet issued.
• Settlement / termination: No information on settlement or termination.
• Appeal: Not applicable as a Final Written Decision has not been issued.
• Defensive value: This proceeding is ongoing, indicating that at least some claims of the patent are facing a validity challenge. If the claims are ultimately invalidated, it would significantly weaken the patent owner's assertion position. If the claims are upheld, it would strengthen the patent against future challenges on the same grounds.

IPR2026-00221 — Merck Sharp & Dohme LLC v. Pogona LLC

• Type: Inter Partes Review
• Filed: 2026-01-26
• Status: Discretionary Denial
• Judge panel: Not publicly available yet.
• Petition grounds: Not publicly available yet.
• Institution decision: Denied. The petition was denied discretionarily on 2026-05-19. The specific reasoning for the discretionary denial is not yet publicly available in the provided snippets.
• Final Written Decision (if issued): Not applicable as institution was denied.
• Settlement / termination: No information on settlement or termination.
• Appeal: No information on appeal to the Federal Circuit.
• Defensive value: The discretionary denial of this IPR means that the patent claims challenged by Merck Sharp & Dohme LLC in this specific proceeding have survived this particular challenge. This makes an IPR-based defense using the same or similar art somewhat harder for future challengers, particularly if the discretionary denial was based on factors beyond the merits of the art (e.g., related litigation).

Strategic summary

As of 2026-05-28, US patent 11058757 has faced two IPR challenges. IPR2026-00221, filed by Merck Sharp & Dohme LLC, resulted in a discretionary denial of institution on 2026-05-19. This means the claims challenged in that petition remain untested by the PTAB. Conversely, IPR2026-00189, filed by Pfizer Inc., has been instituted to trial. The specific claims challenged in this instituted IPR are not yet publicly known, nor are the prior art grounds. Therefore, at this stage, it cannot be definitively stated which claims of US11058757 are canceled, sustained, or remain entirely untested by the PTAB.

Regarding the estoppel landscape, for IPR2026-00221, because institution was denied, statutory estoppel under 35 U.S.C. § 315(e)(1) for instituted grounds does not apply. However, common law estoppel principles might still be argued in certain contexts. For IPR2026-00189, once a Final Written Decision is issued, Pfizer Inc. (and its privies) will be estopped from asserting in future district court or ITC actions any invalidity ground that was raised or reasonably could have been raised during the IPR. The current petitions were filed by major pharmaceutical companies (Merck Sharp & Dohme LLC and Pfizer Inc.), indicating significant interest in challenging the patent. The involvement of Unified Patents as a petitioner in IPR2026-00189 (as indicated in the previous litigation summary, although the PTAB proceedings on file list Pfizer Inc.) suggests a potential strategy of using a defensive aggregator to challenge the patent's validity.

Recommended next steps

For IPR2026-00189, which is currently in trial, monitoring upcoming trial-stage milestones, such as the oral hearing (if scheduled) and the Final Written Decision due date (which will be approximately one year from the institution date), is critical. The institution decision itself, when publicly available, should be reviewed to understand the specific claims and grounds that were advanced to trial. The USPTO PTAB E2E system should be consulted for official documents and dates related to IPR2026-00189: https://e2e.uspto.gov/ptab/.
For IPR2026-00221, the decision for discretionary denial on 2026-05-19 should be analyzed to understand the Board's reasoning, as this can inform future defensive strategies. The document can be found through the USPTO PTAB E2E system: https://e2e.uspto.gov/ptab/.

Inventors

The named inventors for US patent 11058757 are Bruce D. Forrest and Jack D. Love. The patent records do not explicitly state their employers at the time of filing. However, both inventors assigned their interest in the patent application on March 30, 2017, just one day before the patent's filing date, to Liffey Biotech Limited and also directly to Pogona, LLC. This rapid transfer of rights to patent holding entities is a common pattern when individual inventors or small teams seek to commercialize or monetize their intellectual property through such vehicles.

Original assignee

The entity named as the original assignee on the issued patent is Pogona LLC.

Pogona LLC does not appear to ship a product embodying the claims of US11058757. Its primary line of business, as identified by various patent litigation tracking databases and news sources, is patent monetization and assertion. Pogona LLC is currently operating, primarily as a non-practicing entity (NPE) engaged in patent licensing and litigation.

Assignment timeline

The following assignments for US11058757 are recorded with the USPTO:

• 2017-03-30 (executed) / recorded 2019-11-29 — Reel 051770/0090

  • Conveyance: Assignment of Assignors Interest
  • Assignor: FORREST, BRUCE D., LOVE, JACK D.
  • Assignee: LIFFEY BIOTECH LIMITED
  • Correspondent: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 New York Avenue NW, Washington, DC, 20001. This correspondent recurs in this chain.
  • Context: Initial assignment of patent rights from the inventors to a patent holding entity.

• 2019-07-16 (executed) / recorded 2019-07-17 — Reel 052458/0954

  • Conveyance: Assignment of Assignors Interest
  • Assignor: LIFFEY BIOTECH LIMITED
  • Assignee: POGONA, LLC
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 500 North Capitol Street, N.W., Washington, DC, 20001.
  • Context: Transfer of patent rights from one patent holding entity (Liffey Biotech Limited) to another (Pogona, LLC).

• 2017-03-30 (executed) / recorded 2021-05-05 — Reel 056770/0951

  • Conveyance: Assignment of Assignors Interest
  • Assignor: FORREST, BRUCE D., LOVE, JACK D.
  • Assignee: POGONA, LLC
  • Correspondent: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 New York Avenue, NW, Washington, DC, 20001. This correspondent recurs in this chain.
  • Context: A direct assignment from the inventors to Pogona, LLC, executed on the same date as the assignment to Liffey Biotech Limited, but recorded much later. This likely serves as a corrective or clarifying record for the chain of title.

Timeline diagram

timeline
    title Ownership of US 11058757
    2017 : Inventors assign to Liffey Biotech
         : Inventors assign to Pogona LLC
    2019 : Liffey Biotech assigns to Pogona LLC
    2021 : Patent issued

NPE / troll-pattern signals

1. Shell-entity transfer — present. The patent moved from the inventors to Liffey Biotech Limited (a holding company) and then to Pogona, LLC (a known patent monetization entity). Pogona LLC does not produce products embodying the claims. This is supported by the recorded assignments. [cite: Reel 051770/0090, Reel 052458/0954, Reel 056770/0951]
2. Known asserter in the chain — present. Pogona LLC is widely recognized as a non-practicing entity (NPE) or patent assertion entity (PAE).
3. Repeat correspondent across the chain — present. FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP appears as the correspondent on two assignments (Reel 051770/0090 and Reel 056770/0951), both originating from the inventors and executed on the same date (2017-03-30). This recurrence indicates a consistent legal representation for aspects of the patent's ownership transfer.
4. Cascading transfers — present. There were multiple assignments (Inventors to Liffey Biotech, Liffey Biotech to Pogona LLC, and a direct Inventors to Pogona LLC) with complex overlapping execution and recording dates. The transfers occurred within a relatively short period (from 2017 to 2021 to solidify Pogona's ownership). [cite: Reel 051770/0090, Reel 052458/0954, Reel 056770/0951]
5. Pre-litigation transfer — not present. The most recent assignment to Pogona, LLC was recorded on 2021-05-05 (Reel 056770/0951). The first district court case (2:25-cv-15294) was filed in 2025. This gap is greater than 6 months.
6. Bankruptcy fire-sale — not present. There is no indication of the original assignee or any entity in the chain having filed for bankruptcy.
7. Privateering — unclear. While Pogona LLC is an NPE, there is no public information linking its assertion activities to a specific operating company's defensive or competitive strategy against rivals for this patent.
8. Defensive aggregator (anti-NPE) — not present. The chain terminates with Pogona LLC, which is an NPE, not a defensive aggregator.

Verdict

NPE — high confidence. This verdict is supported by the presence of multiple strong signals. Pogona LLC, the current assignee, is a known patent assertion entity, and the patent rights were transferred through at least one other holding company (Liffey Biotech Limited). The complex and somewhat cascading nature of the initial assignments, including a direct assignment from inventors to Pogona LLC recorded significantly later (Reel 056770/0951) but executed on the same date as an earlier assignment to Liffey Biotech Limited (Reel 051770/0090), further suggests a deliberate structuring of ownership typical of NPE strategies.

USPTO Assignment Center Search for US11058757

Prior Art Analysis for US Patent 11058757

To identify the most relevant prior art for US patent 11058757, "Saccharide-polypeptide conjugate compositions and methods of use thereof," a review of the patent's cited references has been conducted. The analysis focuses on how these references might potentially anticipate claims 1, 15, and 16 under 35 U.S.C. § 102.

Patent Citations

The following are some of the key patent citations for US11058757, along with an assessment of their potential anticipatory effect:

1. US 2012/0213803 A1

• Full Citation: US 2012/0213803 A1 (Forrest; Bruce, et al.)
• Publication/Filing Date: Published: August 23, 2012; Filed: December 19, 2011.
• Brief Description: This patent application describes multivalent pneumococcal conjugate vaccines and methods for their preparation and use. It discloses compositions comprising saccharides from multiple Streptococcus pneumoniae serotypes conjugated to a carrier protein. The document emphasizes the importance of selecting carrier proteins and conjugation methods to elicit a broad immune response. For example, it discusses conjugates for numerous S. pneumoniae serotypes (e.g., 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and their use in vaccine formulations.
• Potential Anticipation (35 U.S.C. § 102):
  • Claim 1: This reference potentially anticipates Claim 1. It explicitly discloses pharmaceutical compositions that are multi-component vaccines comprising a mixture of at least five distinct conjugate components, where each component comprises a saccharide from a different Streptococcus pneumoniae serotype (e.g., Serotype 1 saccharide, Serotype 2 saccharide) chemically attached to a polypeptide carrier, and the saccharides are not derived from the polypeptide carrier. The application describes vaccines with more than five serotypes.
  • Claim 15: This reference potentially anticipates Claim 15. It teaches methods for stimulating an immune response in a subject against Streptococcus pneumoniae by administering the described multivalent pneumococcal conjugate vaccine compositions.
  • Claim 16: This reference potentially anticipates Claim 16. It outlines methods for manufacturing such pharmaceutical compositions, including processes for combining multiple conjugate components.

2. US 2007/0071765 A1

• Full Citation: US 2007/0071765 A1 (Love; Jack D., et al.)
• Publication/Filing Date: Published: March 29, 2007; Filed: May 26, 2006.
• Brief Description: This publication relates to carrier proteins suitable for use in conjugate vaccines, particularly for bacterial polysaccharides. It details the use of specific polypeptide carriers, such as a modified diphtheria toxin (CRM197), for conjugating to saccharide antigens to enhance immunogenicity. While not exclusively focused on Streptococcus pneumoniae, it lays groundwork for conjugation chemistry and carrier protein selection relevant to such vaccines.
• Potential Anticipation (35 U.S.C. § 102):
  • Claim 1: This reference contributes to the understanding of saccharide-polypeptide conjugates and carrier proteins. However, it does not explicitly disclose a multi-component vaccine with at least five distinct Streptococcus pneumoniae serotypes in a single composition. Therefore, it may not directly anticipate Claim 1 under § 102, but it is highly relevant for obviousness considerations in combination with other prior art.
  • Claim 15: Similar to Claim 1, while discussing the general principle of stimulating an immune response with conjugate vaccines, it doesn't specifically teach the method of using a multi-component vaccine with at least five S. pneumoniae serotypes.
  • Claim 16: It provides methods for conjugating saccharides to polypeptides, which is a component of Claim 16, but lacks the specific combination of at least five distinct Streptococcus pneumoniae serotypes.

3. US 8,865,183 B2

• Full Citation: US 8,865,183 B2 (Forrest; Bruce D., et al.)
• Publication/Filing Date: Issued: October 21, 2014; Filed: October 28, 2013 (continuation of application Ser. No. 13/469,216, filed May 11, 2012, which is a continuation of Ser. No. 12/624,801, filed Nov. 24, 2009, now Pat. No. 8,206,711).
• Brief Description: This patent is titled "Pneumococcal vaccines and methods of use thereof." It describes conjugate vaccines comprising pneumococcal saccharides from various serotypes (e.g., Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) conjugated to a carrier protein. The patent details the specific ratios and amounts of each conjugate in the vaccine formulation.
• Potential Anticipation (35 U.S.C. § 102):
  • Claim 1: This reference potentially anticipates Claim 1. It clearly discloses pharmaceutical compositions that are multi-component vaccines, including at least five (and often more) distinct conjugate components, where each component features a saccharide from a different Streptococcus pneumoniae serotype chemically attached to a polypeptide carrier, and the saccharides are not derived from the polypeptide carrier.
  • Claim 15: This reference potentially anticipates Claim 15. It explicitly describes methods for stimulating an immune response in a subject against Streptococcus pneumoniae by administering the claimed multivalent pneumococcal conjugate vaccines.
  • Claim 16: This reference potentially anticipates Claim 16. It details manufacturing methods for such vaccine compositions, involving the combination of multiple conjugate components.

4. US 8,663,656 B2

• Full Citation: US 8,663,656 B2 (Anderson; Peter W., et al.)
• Publication/Filing Date: Issued: March 4, 2014; Filed: April 1, 2008.
• Brief Description: This patent, "Pneumococcal saccharide-protein conjugate vaccines," focuses on various Streptococcus pneumoniae serotype polysaccharides conjugated to a carrier protein, such as CRM197. It describes methods for preparing these conjugates and their use in vaccine formulations. The patent explicitly discusses vaccines covering multiple serotypes, including at least some of those covered by US11058757.
• Potential Anticipation (35 U.S.C. § 102):
  • Claim 1: This reference potentially anticipates Claim 1. It describes multivalent pneumococcal conjugate vaccines comprising saccharides from several Streptococcus pneumoniae serotypes conjugated to a polypeptide carrier, meeting the "at least five distinct conjugate components" criterion.
  • Claim 15: This reference potentially anticipates Claim 15. It teaches methods for inducing an immune response in a subject using the disclosed pneumococcal saccharide-protein conjugate vaccines.
  • Claim 16: This reference potentially anticipates Claim 16. It details methods for preparing the conjugate vaccines, which involves combining the various conjugate components.

Summary of Anticipation:

Based on the review, US 2012/0213803 A1, US 8,865,183 B2, and US 8,663,656 B2 appear to be highly relevant prior art that potentially anticipate the independent claims (Claim 1, 15, and 16) of US11058757. These references generally disclose multi-component vaccine compositions comprising saccharides from multiple distinct Streptococcus pneumoniae serotypes conjugated to a polypeptide carrier, as well as methods of using and manufacturing such compositions. The common inventorship and assignee (Pogona LLC is the current assignee of US11058757 and was involved in earlier assignments/filings related to some of these patents) suggest a family of related inventions in the pneumococcal vaccine field. US 2007/0071765 A1, while relevant for its discussion of carrier proteins and conjugation, does not appear to directly anticipate the "at least five distinct Streptococcus pneumoniae serotypes" requirement in a single composition, making it more relevant for obviousness arguments.

Obviousness Analysis of US Patent 11058757 Under 35 U.S.C. § 103

This analysis identifies combinations of prior art references that would render the claims of US patent 11058757 obvious to a person having ordinary skill in the art (PHOSITA). The patent, titled "Saccharide-polypeptide conjugate compositions and methods of use thereof," generally covers multi-component pneumococcal conjugate vaccines. The critical aspects of the independent claims revolve around a pharmaceutical composition comprising at least five distinct saccharide-polypeptide conjugate components from different Streptococcus pneumoniae serotypes, methods of use, and manufacturing processes.

Understanding the Person Having Ordinary Skill in the Art (PHOSITA)

A PHOSITA in the field of pneumococcal conjugate vaccines would possess knowledge of microbiology, immunology, biochemistry, and pharmaceutical formulation. This includes understanding the principles of antigen presentation, immunogenicity of saccharides and proteins, methods for conjugating saccharides to carrier proteins, and the development of multi-valent vaccines to target various serotypes of a pathogen like Streptococcus pneumoniae. They would also be aware of the existing pneumococcal vaccines, such as the polysaccharide vaccines (e.g., PPSV23) and earlier conjugate vaccines (e.g., PCV7, PCV13).

Prior Art References

The examination of US11058757 reveals a lengthy list of cited U.S. patents, predominantly by Giebink et al., covering various aspects of pneumococcal conjugate vaccines. For the purpose of this obviousness analysis, we will focus on key representative prior art documents that broadly cover the claimed elements:

• US5623057A (Giebink et al.): This patent describes conjugate vaccines comprising partially hydrolyzed capsular polysaccharide (Ps) from Streptococcus pneumoniae linked to an immunogenic carrier protein. It also explicitly teaches vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein conjugates, which induce broadly protective immune responses against the cognate pathogens. It lists numerous serotypes, including 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F, as potential components.
• WO2015144031A1: This publication discloses a Streptococcus pneumoniae polysaccharide protein conjugated vaccine comprising one or multiple immune conjugates where capsular polysaccharide is coupled with protein. It specifically mentions that the capsular polysaccharide can be isolated from various serotypes including 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. The document further discusses a 7-valent pneumococcal protein vaccine and a 13-valent conjugate vaccine in development by Pfizer.
• WO2007071707A2: This reference provides a multivalent Streptococcus pneumoniae immunogenic composition with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to two or more different carrier proteins.
• "Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods" (PMC, 2022): This review article discusses the state of the art in S. pneumoniae glycoconjugate vaccines, noting that such vaccines are generally prepared by coupling native or sized polysaccharides to a carrier protein. It highlights the use of CRM197 (a diphtheria toxoid mutant) and other proteins like diphtheria toxoid (DT) and tetanus toxoid (TT) as carrier proteins in existing vaccines such as Prevnar and Synflorix. It also mentions that Avery conjugated pneumococcal polysaccharides to proteins in 1929 to improve immunogenicity.
• "Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses" (PMC, 2022): This article discusses two pneumococcal vaccines in current use: PPSV23 (23-valent polysaccharide vaccine) and PCV13 (13-valent glycoconjugate vaccine). It confirms that PCV13 elicits IgG and OPA titers against various serotypes including 1, 3, 6A, 6B, 7F, 19A, 19F, and 23F, using carrier protein CRM.

Obviousness Arguments

Claim 1: Pharmaceutical Composition

Claim 1 protects a pharmaceutical composition comprising a mixture of at least five distinct saccharide-polypeptide conjugate components, each with a saccharide from a unique Streptococcus pneumoniae serotype, chemically attached to a polypeptide carrier, where the saccharides are not derived from the polypeptide carrier.

Combination of US5623057A and the general knowledge in the art:

US5623057A explicitly teaches a novel conjugate vaccine comprising capsular polysaccharide from Streptococcus pneumoniae linked to an immunogenic carrier protein. It further teaches that vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein conjugates are effective in inducing broadly protective immune responses. The patent lists numerous distinct S. pneumoniae serotypes. This reference directly anticipates or makes obvious the concept of a multi-component vaccine where each component consists of a saccharide from a distinct Streptococcus pneumoniae serotype conjugated to a polypeptide carrier.

A PHOSITA, faced with the goal of creating a vaccine against a broader range of S. pneumoniae serotypes, would have a clear motivation to combine more than one conjugate component from different serotypes, as taught by US5623057A. The selection of at least five distinct serotypes would be a matter of routine optimization, driven by epidemiological data on prevalent serotypes, without requiring undue experimentation. Indeed, the art already practiced vaccines like PCV7 and PCV13, demonstrating the common practice of combining multiple serotypes. The requirement that the saccharides are not derived from the polypeptide carrier is inherent to the definition of a conjugate vaccine where a foreign antigen (saccharide) is linked to a carrier molecule (polypeptide) to enhance immunogenicity. Therefore, a PHOSITA would find it obvious to formulate a pharmaceutical composition containing at least five distinct conjugate components as claimed in Claim 1.

Motivation to combine: The primary motivation would be to broaden the protective efficacy of the vaccine against a wider array of Streptococcus pneumoniae serotypes, a long-standing goal in vaccine development. The art, as exemplified by US5623057A and other references (e.g., WO2015144031A1 and the discussion of PCV13), clearly teaches the benefit of multivalent conjugate vaccines.

Claim 15: Method of Treatment

Claim 15 covers a method for stimulating an immune response in a subject against Streptococcus pneumoniae by administering the pharmaceutical composition of Claim 1.

Combination of US5623057A and general medical knowledge:

US5623057A explicitly states that its conjugate vaccines are "useful in the prevention of pneumococcal infections" and that they "induce broadly protective recipient immune responses." Administering a vaccine to stimulate an immune response is the fundamental purpose and well-known method of use for any vaccine. A PHOSITA, upon developing or obtaining the vaccine composition described in Claim 1 (which itself would be obvious), would find it obvious to administer it to a subject to elicit an immune response against Streptococcus pneumoniae.

Motivation to combine: The motivation to administer the vaccine is self-evident: to protect subjects from Streptococcus pneumoniae infections. This is the intended purpose of vaccine development and a routine clinical step known to any PHOSITA.

Claim 16: Manufacturing Method

Claim 16 outlines a manufacturing method for the pharmaceutical composition, involving combining at least five separate conjugate components, each featuring a saccharide from a different Streptococcus pneumoniae serotype covalently linked to a polypeptide, where the saccharides are not derived from the polypeptide.

Combination of US5623057A, WO2015144031A1, and common knowledge in pharmaceutical manufacturing:

US5623057A describes the production of conjugate vaccines and mentions mixtures of such conjugates. WO2015144031A1 further details the separation and purification of capsular polysaccharides and carrier proteins, and the coupling methods for preparing pneumococcal protein vaccines. The reference also mentions the selection of multiple serotypes for vaccine preparation, such as 24 serotypes for purification.

A PHOSITA would know that creating a multi-component vaccine involves preparing each conjugate component individually and then combining them to form the final vaccine composition. The manufacturing process of "combining at least five separate conjugate components" is a straightforward and conventional step in formulating multivalent vaccines. This is explicitly taught by the prior art, which discusses multi-valent pneumococcal vaccines. The methods for isolating polysaccharides and coupling them to carrier proteins are also described as "prior art which has been mastered by a person skilled in the art."

Motivation to combine: The motivation for combining individually prepared conjugate components is to create a single, administrable multi-valent vaccine product that provides broad protection against multiple serotypes, which is a desirable and known outcome in vaccine manufacturing. The process of combining different components to achieve a desired multi-valent formulation is standard practice in pharmaceutical composition, requiring no inventive step.

Conclusion on Obviousness

The independent claims of US patent 11058757 appear to be obvious under 35 U.S.C. § 103 in light of the cited prior art. The concept of creating multi-component saccharide-polypeptide conjugate vaccines against Streptococcus pneumoniae using distinct serotypes, methods of administering such vaccines to stimulate an immune response, and the manufacturing process of combining these components were all well-established in the art prior to the priority date of US11058757. Specifically, US5623057A and other contemporary references clearly disclose the core elements of the claims, and a PHOSITA would have been motivated to combine these teachings to create the claimed invention for the evident benefit of broader protective immunity. Further, the method claims and manufacturing claims rely on the obviousness of the composition and standard industry practices.